Cargando…

The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.

Fifty-three premenopausal patients presenting with advanced breast cancer have been treated with a potent new luteinising hormone-releasing hormone agonist Zoladex (ICI 118630) in a phase I clinical trial. On progression of disease 26 patients have undergone therapeutic oophorectomy. We present the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Williams, M. R., Walker, K. J., Turkes, A., Blamey, R. W., Nicholson, R. I.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1986
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001373/ https://www.ncbi.nlm.nih.gov/pubmed/2941044

Ejemplares similares

Response in post-menopausal patients on ICI 118630.
por: Robertson, J. F., et al.
Publicado: (1987)

Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.
por: Dixon, A. R., et al.
Publicado: (1990)

Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.
por: Plowman, P. N., et al.
Publicado: (1986)

Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.
por: Nicholson, R. I., et al.
Publicado: (1979)

Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
por: Cheng, Tsui Fen, et al.
Publicado: (2012)

Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1989)

pS6K1 as an efficacy marker of GnRH agonist with premenopausal breast cancer
por: Park, Chan Sub, et al.
Publicado: (2019)

Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women
por: Jonat, W
Publicado: (2002)

Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women
por: Jonat, W
Publicado: (2001)

Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial
por: NISHIMURA, REIKI, et al.
Publicado: (2013)

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer.
por: Howell, A., et al.
Publicado: (1996)

Unsuspected Skin Metastasis of Adenocarcinoma of the Prostate in a Patient on Goserelin (Zoladex)
por: Mbaeri, Timothy Uzoma, et al.
Publicado: (2018)

The value of LH maximum level in predicting optimal oocyte yield following GnRH agonist trigger
por: Lee, William Hao-Yu, et al.
Publicado: (2023)

An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data.
por: Williams, M. R., et al.
Publicado: (1990)

A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
por: Lind, M. J., et al.
Publicado: (1992)

Orchiectomy versus medical therapy with LH-RH analogues for the treatment of advanced prostatic carcinoma
por: Rohde, Volker, et al.
Publicado: (2006)

The Effect of Photoperiodic Conditions on GnRH/LH Secretion in Ewes
por: Kopycińska, Kamila, et al.
Publicado: (2022)

Self-Detection of the LH Surge in Urine After GnRH Agonist Trigger in IVF—How to Minimize Failure to Retrieve Oocytes
por: Cozzolino, Mauro, et al.
Publicado: (2020)

GnRH and LHR gene variants predict adverse outcome in premenopausal breast cancer patients
por: Piersma, Djura, et al.
Publicado: (2007)

Using Aptamers as a Novel Method for Determining GnRH/LH Pulsatility
por: Izzi-Engbeaya, Chioma, et al.
Publicado: (2020)

Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer
por: Torrisi, R, et al.
Publicado: (2007)

Effects of recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-agonist protocol: a matched case-control study
por: Franco, José G, et al.
Publicado: (2009)

Low Endogenous LH on the COS Initiation Day of a GnRH-Agonist Regimen Increases the Risk of Early Pregnancy Loss and Adverse ART Outcomes
por: Luo, Xi, et al.
Publicado: (2022)

ICIS05 CONFERENCE
por: Lau, C, et al.
Publicado: (02/1)

GnRH agonist-triggering ovulation in women with advanced age
por: Rahav Koren, Roni, et al.
Publicado: (2022)

Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2015)

ICI 182,780 has agonistic effects and synergizes with estradiol-17 beta in fish liver, but not in testis
por: Pinto, Patrícia IS, et al.
Publicado: (2006)

A mathematical model for LH release in response to continuous and pulsatile exposure of gonadotrophs to GnRH
por: Washington, Talitha M, et al.
Publicado: (2004)

A Two-Pathway Mathematical Model of the LH Response to GnRH that Predicts Self-Priming
por: Evans, J. J., et al.
Publicado: (2013)

Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer.
por: Robertson, J. F., et al.
Publicado: (1992)

Family history and survival in premenopausal breast cancer.
por: Mohammed, S. N., et al.
Publicado: (1998)

The Icy Realm of the Rime
por: Potter, Polyxeni
Publicado: (2011)

Body size and survival in premenopausal breast cancer.
por: Greenberg, E. R., et al.
Publicado: (1985)

The GLP-1 agonist, exendin-4, stimulates LH secretion in female sheep
por: Simpson, Elizabeth M, et al.
Publicado: (2023)

Live-birth rates after HP-hMG stimulation in the long GnRH agonist protocol: association with mid-follicular hCG and progesterone concentrations, but not with LH concentrations
por: Arce, Joan-Carles, et al.
Publicado: (2013)

Eel Kisspeptins: Identification, Functional Activity, and Inhibition on both Pituitary LH and GnRH Receptor Expression
por: Pasquier, Jérémy, et al.
Publicado: (2018)

Determination of Half-lives of Circulating FSH and LH Glycoforms in Women During GnRH Receptor Blockade
por: Wide, Leif, et al.
Publicado: (2022)

The molecular landscape of premenopausal breast cancer
por: Liao, Serena, et al.
Publicado: (2015)

Lipidome of mammographic breast density in premenopausal women
por: Getz, Kayla R., et al.
Publicado: (2023)

Follicular-Phase GnRH Agonist Protocol Is Another Choice for Polycystic Ovary Syndrome Patients With Lower LH/FSH and Lower AMH Levels Without Increasing Severe OHSS Risk
por: Gao, Rui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jk1p3inrpnnej19b55caerugoh